Philip Beer MRCP, FRCPath, PhD
Dr Philip Beer is a Physician Scientist and precision oncology specialist who operates across the commercial, academic and healthcare sectors. Philip holds diverse positions united by the singular goal of leveraging genomic technologies to improve outcomes for cancer patients, with a specific focus on the clinical implementation of cancer genomic platforms and the interpretation of the output data for use in routine oncology practice. Philip trained as a haematologist at Imperial College, London, followed by academic research at the University of Cambridge and the BC Cancer Agency, Vancouver. Current roles include work as a molecular and cellular pathologist at a flagship NHS diagnostic unit, clinical support for a leading commercial provider of cancer genomic analysis, translational support for early clinical stage oncology drug development in the pharmaceutical sector, and involvement in academic research projects encompassing cancer genomics and functional modelling.
The evolution of oncology therapeutics in the genomic era.
Parallel advances in sequencing technology and synthetic chemistry have delivered a near-complete lexicon of genomic cancer drivers alongside the ability to target with therapeutic intent a diverse range of oncogenic molecules. Despite this progress, however, the impact of molecularly-targeted therapy has to date been relatively modest. Important barriers to the full realisation of the power of cancer genomics include the availability and reimbursement of genomic testing, access to suitably comprehensive testing, identification of biologically significant (‘driver’) mutations, and the reporting of complex genomic data in a clinically meaningful way. Perhaps most significant of all is a pressing need to re-evaluate approaches to clinical trial design and patient stratification in light of recent advances in our understanding of how cancers evolve to evade targeted and immune-based therapies.
EVEN MORE SEMINARS
Emlyn Samuel Cancer Research UK
Brexit: getting the best outcome for research and patients
Glenn Flux Royal Marsden Hospital
The emergence and resurgence of radiotherapeutics for cancer treatment
Mr Naga Venkatesh Jayanthi MD, FRCS Bupa - Consultant Surgeon
Minimal Invasive Oesophagectomy – where are we going?
Nizar Asadi Royal Brompton & Harefield NHS Foundation Trust
Thoracic surgery in the treatment of lung cancer
Dr Tom Newsom-Davis Leaders in Oncology Care (Part of HCA healthcare UK)
Immunotherapy and innovative systemic treatments in Oncology